What are the main challenges that you come across as a small biotechnology company?
TC. As we are a small company, when we decided to exit the chemistry services business and move into full-time discovery and development, finding the staff that had that kind of experience and knowledge was a challenge. We had to restructure corporate activities normally carried out by 300 chemists toward how to deal with clinical trials. That was a huge transition – to trade in one skill set for another to allow us to do what was needed was hard on everyone. But, it’s beginning to work out for us. Recruiting has always been a challenge, especially in the Boston area. So many biotech and pharmaceutical companies are there, but I believe that we bring in the right people, and hopefully with some of the newer technologies coming into play, that will help in the process of recruiting too. • NGP. And what’s in the pipeline for ArQule in the next 10 years? TC. Hopefully our productivity will go up. If you look at our industry as a whole, 15 years ago, for every 100 compounds that were put i
